A garlic derivative, s-allylcysteine (sac), suppresses proliferation and metastasis of hepatocellular carcinoma

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Ng, Kevin T P ^a   Guo, Dong Yong ^a,b   Cheng, Qiao ^a   Geng, Wei ^a   Ling, Chang Chun ^a   Li, Chang Xian ^a   Liu, Xiao Bing ^a   Ma, Yuen Yuen ^a   Lo, Chung Mau ^a   Poon, Ronnie T P ^a   Fan, Sheung Tat ^a   Man, Kwan ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLINE; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN TYROSINE PHOSPHATASE; S ALLYLCYSTEINE; UVOMORULIN; VASCULOTROPIN; CYSTEINE; DRUG DERIVATIVE; S-ALLYLCYSTEINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; GARLIC; LIVER TUMOR; METABOLISM; METASTASIS; NUDE MOUSE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ALLIUM SATIVUM;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTEINE; GARLIC; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84863253114     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031655     Document Type: Article

References (33)

1. Yang JD, Roberts LR, (2010) Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7: 448-458.
2. Yau T, Chan P, Epstein R, Poon RT, (2009) Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 29: 10-17.
3. Rivlin RS, (2001) Historical perspective on the use of garlic. The Journal of nutrition 131: 951S-954S.
4. Thomson M, Ali M, (2003) Garlic [Allium sativum]: a review of its potential use as an anti-cancer agent. Current cancer drug targets 3: 67-81.
5. Powolny AA, Singh SV, (2008) Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer letters 269: 305-314.
6. Herman-Antosiewicz A, Singh SV, (2004) Signal transduction pathways leading to cell cycle arrest and apoptosis induction in cancer cells by Allium vegetable-derived organosulfur compounds: a review. Mutation research 555: 121-131.
7. Chu Q, Ling MT, Feng H, Cheung HW, Tsao SW, et al. (2006) A novel anticancer effect of garlic derivatives: inhibition of cancer cell invasion through restoration of E-cadherin expression. Carcinogenesis 27: 2180-2189.
8. Chu Q, Lee DT, Tsao SW, Wang X, Wong YC, (2007) S-allylcysteine, a water-soluble garlic derivative, suppresses the growth of a human androgen-independent prostate cancer xenograft, CWR22R, under in vivo conditions. BJU Int 99: 925-932.
9. Gapter LA, Yuin OZ, Ng KY, (2008) S-Allylcysteine reduces breast tumor cell adhesion and invasion. Biochem Biophys Res Commun 367: 446-451.
10. Tang FY, Chiang EP, Chung JG, Lee HZ, Hsu CY, (2009) S-allylcysteine modulates the expression of E-cadherin and inhibits the malignant progression of human oral cancer. J Nutr Biochem 20: 1013-1020.
11. Welch C, Wuarin L, Sidell N, (1992) Antiproliferative effect of the garlic compound S-allyl cysteine on human neuroblastoma cells in vitro. Cancer letters 63: 211-219.
12. Tang FY, Chiang EP, Pai MH, (2010) Consumption of S-Allylcysteine Inhibits the Growth of Human Non-Small-Cell Lung Carcinoma in a Mouse Xenograft Model. J Agric Food Chem.
13. Tanaka S, Haruma K, Yoshihara M, Kajiyama G, Kira K, et al. (2006) Aged garlic extract has potential suppressive effect on colorectal adenomas in humans. The Journal of nutrition 136: 821S-826S.
14. Sundaresan S, Subramanian P, (2008) Prevention of N-nitrosodiethylamine-induced hepatocarcinogenesis by S-allylcysteine. Mol Cell Biochem 310: 209-214.
15. Li Y, Tang ZY, Ye SL, Liu YK, Chen J, et al. (2001) Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 7: 630-636.
16. Man K, Ng KT, Xu A, Cheng Q, Lo CM, et al. (2010) Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res 16: 967-977.
17. Ng KT, Qi X, Kong KL, Cheung BY, Lo CM, et al. (2011) Overexpression of matrix metalloproteinase-12 (MMP-12) correlates with poor prognosis of hepatocellular carcinoma. Eur J Cancer.
18. Lee TK, Man K, Ho JW, Wang XH, Poon RT, et al. (2005) FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res 11: 8458-8466.
19. Stroescu C, Dragnea A, Ivanov B, Pechianu C, Herlea V, et al. (2008) Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointestin Liver Dis 17: 411-417.
20. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
21. Shirin H, Pinto JT, Kawabata Y, Soh JW, Delohery T, et al. (2001) Antiproliferative effects of S-allylmercaptocysteine on colon cancer cells when tested alone or in combination with sulindac sulfide. Cancer research 61: 725-731.
22. Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S, (2001) Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 33: 346-356.
23. Boutros R, Lobjois V, Ducommun B, (2007) CDC25 phosphatases in cancer cells: key players? Good targets? Nature reviews Cancer 7: 495-507.
24. Knowles LM, Milner JA, (2000) Diallyl disulfide inhibits p34(cdc2) kinase activity through changes in complex formation and phosphorylation. Carcinogenesis 21: 1129-1134.
25. Li KK, Ng IO, Fan ST, Albrecht JH, Yamashita K, et al. (2002) Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma. Liver 22: 259-268.
26. Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, et al. (2000) Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 59: 68-74.
27. Wysocki PJ, (2010) Targeted therapy of hepatocellular cancer. Expert Opin Investig Drugs 19: 265-274.
28. Ng KT, Lee TK, Cheng Q, Wo JY, Sun CK, et al. (2010) Suppression of tumorigenesis and metastasis of hepatocellular carcinoma by shRNA interference targeting on homeoprotein Six1. Int J Cancer 127: 859-872.
29. Steeg PS, (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12: 895-904.
30. Cho SB, Lee KH, Lee JH, Park SY, Lee WS, et al. (2008) Expression of E- and N-cadherin and clinicopathology in hepatocellular carcinoma. Pathol Int 58: 635-642.
31. Fransvea E, Angelotti U, Antonaci S, Giannelli G, (2008) Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology.
32. Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, et al. (2008) Biology of hepatocellular carcinoma. Ann Surg Oncol 15: 962-971.
33. Zhu AX, Duda DG, Sahani DV, Jain RK, (2011) HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol.